Cargando…
Association of Serum and Fecal Bile Acid Patterns With Liver Fibrosis in Biopsy-Proven Nonalcoholic Fatty Liver Disease: An Observational Study
INTRODUCTION: No reports on both blood and fecal bile acids (BAs) in patients with nonalcoholic fatty liver disease (NAFLD) exist. We simultaneously assessed the serum and fecal BA patterns in healthy participants and those with NAFLD. METHODS: We collected stool samples from 287 participants from 5...
Autores principales: | Kasai, Yuki, Kessoku, Takaomi, Tanaka, Kosuke, Yamamoto, Atsushi, Takahashi, Kota, Kobayashi, Takashi, Iwaki, Michihiro, Ozaki, Anna, Nogami, Asako, Honda, Yasushi, Ogawa, Yuji, Kato, Shingo, Imajo, Kento, Higurashi, Takuma, Hosono, Kunihiro, Yoneda, Masato, Usuda, Haruki, Wada, Koichiro, Kawanaka, Miwa, Kawaguchi, Takumi, Torimura, Takuji, Kage, Masayoshi, Hyogo, Hideyuki, Takahashi, Hirokazu, Eguchi, Yuichiro, Aishima, Shinichi, Kobayashi, Noritoshi, Sumida, Yoshio, Honda, Akira, Oyamada, Shunsuke, Shinoda, Satoru, Saito, Satoru, Nakajima, Atsushi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476812/ https://www.ncbi.nlm.nih.gov/pubmed/35616321 http://dx.doi.org/10.14309/ctg.0000000000000503 |
Ejemplares similares
-
Comparison of long‐term prognosis between non‐obese and obese patients with non‐alcoholic fatty liver disease
por: Iwaki, Michihiro, et al.
Publicado: (2022) -
Endotoxins and Non-Alcoholic Fatty Liver Disease
por: Kessoku, Takaomi, et al.
Publicado: (2021) -
Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan
por: Yoneda, Masato, et al.
Publicado: (2021) -
The Role of Leaky Gut in Nonalcoholic Fatty Liver Disease: A Novel Therapeutic Target
por: Kessoku, Takaomi, et al.
Publicado: (2021) -
Combined, elobixibat, and colestyramine reduced cholesterol toxicity in a mouse model of metabolic dysfunction-associated steatotic liver disease
por: Iwaki, Michihiro, et al.
Publicado: (2023)